Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront. The total value of the deal could rise to $1 ...
A multi-institute team led by St. Jude Children's Research Hospital and UT Southwestern Medical Center investigators established for the first time how certain drugs used to treat epilepsy affect ...
A multi-institute team led by St. Jude Children's Research Hospital and UT Southwestern Medical Center investigators established for the first time how certain drugs used to treat epilepsy affect ...
A multi-institute team led by St. Jude Children’s Research Hospital and UT Southwestern Medical Center investigators established for the first time how certain drugs used to treat epilepsy affect ...
Syndesi Therapeutics has launched with about $21 million in funding from investors including UCB and Johnson & Johnson. Based at J&J’s JLINX incubator in Beerse, Belgium, Syndesi will develop small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback